SA
LRMR icon

Strategic Advocates’s Larimar Therapeutics LRMR Stock Holding History

Strategic Advocates’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,350
Closed -$9.19K – 465
2025
Q4 		$9.19K Hold
2,350
– – ﹤0.01% 372
2025
Q3 		$7.59K Buy
+2,350
New +$8.81K ﹤0.01% 375

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Strategic Advocates's LRMR Position: Q1 2026 in Review

Strategic Advocates sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 2,350 shares — an estimated $9.19K sold.

Strategic Advocates first reported a position in LRMR in Q3 2025 and held it in 2 quarters. The position peaked at $9.19K in Q4 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Strategic Advocates reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Strategic Advocates sold 2,350 Larimar Therapeutics shares in Q1 2026, an estimated $9.19K.
  • Strategic Advocates first reported a position in Larimar Therapeutics in Q3 2025 and held it in 2 quarters.
  • Strategic Advocates's Larimar Therapeutics position peaked at $9.19K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.